Oleunor N9e (Valine, Alanine, Arginine, Histidine, Isoleucine, Leucine, Methionine, Phenylalanine, Proline, Serin)

The blend supplies both essential and non‑essential amino acids that are directly absorbed into the bloodstream. Cells use these building blocks for protein synthesis, while the amino acids also activate metabolic pathways such as mTOR, promoting tissue repair and restoring metabolic equilibrium without relying on gut absorption.

The dose of Oleunor N9e is individualized by the prescribing clinician based on the patient’s weight, clinical condition, and nutritional requirements. Healthcare professionals calculate the appropriate volume and infusion rate to meet specific amino acid targets for each patient.

Safety data for Oleunor N9e in pregnancy and lactation are limited. It should only be used if the potential benefit to the mother outweighs any possible risk to the fetus or infant, and the decision must be made by a qualified healthcare provider.

To order Oleunor N9e, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain if needed), and import documentation.

Oleunor N9e offers a balanced profile of essential and non‑essential amino acids similar to other commercial amino acid solutions, but its specific formulation may differ in individual amino‑acid concentrations. Clinicians choose a product based on compatibility with other infusions, electrolyte content, and institutional protocols.

Oleunor N9e must be stored at 2‑8 °C, protected from light, and kept in its original container. Do not freeze or shake the solution. Before use, inspect for particulate matter or discoloration and allow the product to reach room temperature if required for infusion.

Oleunor N9e is administered intravenously as a sterile solution. It is typically infused through a dedicated line or compatible IV set, following aseptic technique. The infusion rate is set according to the prescribed dose and patient tolerance, with regular monitoring of vital signs and laboratory parameters.

Serious risks include anaphylactic reactions, metabolic acidosis, and renal dysfunction, especially in patients with pre‑existing kidney disease or electrolyte disturbances. Prompt recognition and management of these events are essential, and patients should be monitored closely during and after infusion.

Oleunor N9e should be avoided in individuals with known hypersensitivity to any of its amino acid components or to the formulation excipients. It is also contraindicated in patients with severe metabolic disorders that could be worsened by amino‑acid loading, unless a specialist determines that benefits outweigh risks.